Charles Schwab Investment Management Inc Atara Biotherapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$0.44 - $1.22 $7,134 - $19,782	16,215 Added 2.18%	761,360 $525,000
Q4 2023 Feb 06, 2024	SELL	$0.23 - $1.74 $11,134 - $84,236	-48,412 Reduced 6.1%	745,145 $380,000
Q3 2023 Nov 08, 2023	BUY	$1.41 - $2.31 $131,866 - $216,035	93,522 Added 13.36%	793,557 $1.17 Million
Q2 2023 Aug 09, 2023	BUY	$1.5 - $3.04 $59,941 - $121,481	39,961 Added 6.05%	700,035 $1.13 Million
Q1 2023 May 11, 2023	SELL	$2.8 - $5.46 $134,092 - $261,479	-47,890 Reduced 6.76%	660,074 $1.91 Million
Q4 2022 Feb 13, 2023	BUY	$2.85 - $5.18 $63,968 - $116,265	22,445 Added 3.27%	707,964 $2.32 Million
Q3 2022 Nov 14, 2022	BUY	$2.85 - $8.73 $49,809 - $152,574	17,477 Added 2.62%	685,519 $2.59 Million
Q2 2022 Aug 15, 2022	BUY	$4.69 - $9.84 $122,723 - $257,483	26,167 Added 4.08%	668,042 $5.21 Million
Q1 2022 May 13, 2022	BUY	$8.44 - $16.89 $214,494 - $429,242	25,414 Added 4.12%	641,875 $5.96 Million
Q4 2021 Feb 11, 2022	BUY	$14.7 - $19.89 $469,400 - $635,127	31,932 Added 5.46%	616,461 $9.72 Million
Q3 2021 Nov 16, 2021	BUY	$11.99 - $17.9 $53,103 - $79,279	4,429 Added 0.76%	584,529 $10.5 Million
Q2 2021 Aug 16, 2021	BUY	$12.89 - $16.58 $189,792 - $244,123	14,724 Added 2.6%	580,100 $9.02 Million
Q1 2021 May 17, 2021	BUY	$14.0 - $20.72 $798,154 - $1.18 Million	57,011 Added 11.21%	565,376 $8.12 Million
Q4 2020 Feb 16, 2021	BUY	$12.67 - $26.23 $329,787 - $682,740	26,029 Added 5.4%	508,365 $9.98 Million
Q3 2020 Nov 13, 2020	BUY	$11.92 - $15.87 $1.08 Million - $1.44 Million	90,508 Added 23.1%	482,336 $6.25 Million
Q2 2020 Aug 14, 2020	BUY	$7.53 - $14.93 $302,389 - $599,558	40,158 Added 11.42%	391,828 $5.71 Million
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $112,428 - $351,315	19,759 Added 5.95%	351,670 $2.99 Million
Q4 2019 Feb 07, 2020	BUY	$10.89 - $16.79 $89,091 - $137,358	8,181 Added 2.53%	331,911 $5.47 Million
Q3 2019 Nov 08, 2019	BUY	$12.03 - $19.94 $686,888 - $1.14 Million	57,098 Added 21.41%	323,730 $4.57 Million
Q2 2019 Aug 09, 2019	BUY	$19.05 - $41.04 $224,104 - $482,794	11,764 Added 4.62%	266,632 $5.36 Million
Q1 2019 May 14, 2019	BUY	$28.4 - $41.74 $392,232 - $576,471	13,811 Added 5.73%	254,868 $10.1 Million
Q4 2018 Feb 14, 2019	SELL	$30.9 - $42.97 $31,054 - $43,184	-1,005 Reduced 0.42%	241,057 $8.38 Million
Q3 2018 Nov 13, 2018	BUY	$35.05 - $43.5 $620,735 - $770,385	17,710 Added 7.89%	242,062 $10 Million
Q2 2018 Aug 08, 2018	BUY	$35.15 - $51.45 $1.18 Million - $1.72 Million	33,472 Added 17.54%	224,352 $8.25 Million
Q1 2018 May 07, 2018	BUY	$18.0 - $48.35 $1.55 Million - $4.17 Million	86,268 Added 82.46%	190,880 $7.45 Million
Q4 2017 Jan 17, 2018	BUY	$13.2 - $18.1 $237,534 - $325,709	17,995 Added 20.78%	104,612 $1.89 Million
Q3 2017 Nov 13, 2017	BUY	$13.25 - $17.05 $1.15 Million - $1.48 Million	86,617	86,617 $1.43 Million

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.25B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account